Maeda Fumi, Gan Shotaro, Yamada Azusa, Kajiyama Daisuke, Tokitou Fumiaki, Kawaguchi Machiko, Amagasa Hidetoshi, Motoyama Kazuo, Ganno Hideaki, Imai Kenichiro, Ami Katsunori, Iida Satoru, Fukuda Akira, Ando Masayuki, Okano Yoshihiko
Dept. of Surgery, Tokyo Metropolitan Health and Medical Corporation Toshima Hospital.
Gan To Kagaku Ryoho. 2021 Mar;48(3):419-421.
Trifluridine/tipiracil (TAS-102) is an important chemotherapeutic agent recommended by the Japanese guidelines as third- or fourth-line treatment for colorectal cancer. Some studies have reported that administration of TAS-102 concomitant with bevacizumab prolongs progression-free and overall survival in colorectal cancer. We describe 2 patients treated with a chemotherapeutic regimen comprising TAS-102 concomitant with bevacizumab for recurrent colorectal cancer. No adverse events ≥Grade 3(except for hematotoxicity)were observed in these patients. The patient received several courses of chemotherapy with adjustments of the dose and dosing intervals to prevent neutropenia. Combination therapy using TAS-102 and bevacizumab is a feasible Late-line chemotherapeutic regimen for colorectal cancer.
曲氟尿苷/替匹嘧啶（TAS-102）是一种重要的化疗药物，被日本指南推荐作为结直肠癌的三线或四线治疗药物。一些研究报告称，TAS-102与贝伐单抗联合使用可延长结直肠癌患者的无进展生存期和总生存期。我们描述了2例接受包含TAS-102与贝伐单抗联合的化疗方案治疗复发性结直肠癌的患者。这些患者未观察到≥3级不良事件（血液毒性除外）。患者接受了几个疗程的化疗，并调整了剂量和给药间隔以预防中性粒细胞减少。TAS-102与贝伐单抗联合治疗是一种可行的晚期结直肠癌化疗方案。
